CTOP和CHOP方案治疗外周T细胞淋巴瘤的临床随访分析  

Long-term results of CTOP versus CHOP regimens on peripheral T-cell lymphoma

作　　者：余延芳[1] 方志坚[1] 田小园[1] 刘芳[1] 王明迪[1] 李德津[1] 

机构地区：[1]北京大学首钢医院血液内科,北京100144

出　　处：《中国肿瘤临床与康复》2011年第4期356-358,361,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的比较含吡喃阿霉素(THP)的CTOP方案与含阿霉素(ADM)的CHOP方案治疗外周T细胞淋巴瘤(PTCL)的疗效和不良反应。方法回顾性分析外周T细胞淋巴瘤临床特征,比较两种方案的不良反应、近期疗效和远期疗效。结果 29例PTCL中,可行疗效评估的25例,其中CTOP组14例,CHOP组11例;中位随访21.25个月。两组患者临床特征的均衡性比较好。CTOP组和CHOP组的总有效率、完全缓解率分别是78.6%和72.7%(P>0.05)、57.1%和54.5%(P>0.05),3,5年总生存率分别为57.7%和46.3%、32.1%和22.1%(P=0.012),CTOP组有好转趋势。25例患者共接受169个疗程化疗。骨髓抑制为主要不良反应,但两组差异无显著性(P>0.05),CHOP组心脏毒性、脱发、呕吐发生率明显高于CTOP组(P<0.05)。结论采用含THP的CTOP治疗PTCL疗效好,毒性较低,远期生存率较高,尤其对老年PTCL值得临床进一步研究。Objective To compare the efficacy and toxicity of CTOP（with THP）and CHOP（with ADM） in the treatment of peripheral T-cell lymphoma（PTCL）.Methods The clinical characteristics of PTCL were reviewed,and the rate of response,toxicity and long-term survival were analysed retrospectively.Results Twenty-five of 29 patients with PTCL could be evaluated,of them,14 were treated with CTOP and 11 with CHOP regimen with a median follow up of 21.25 months.The clinical characteristics of the two groups were similar.The response rates for CTOP and CHOP were 78.6% and 72.7%,respectively（P0.05）,and the complete remission rates were 57.1% and 54.5%,respectively（P0.05）.The 3-year overall survival rates were 57.7% and 46.3%,and 5-year overall survival rates were 32.1% and 22.1%,respectively（P=0.012）.169 courses were administered in 25 patients.The major toxicity was myelosuppression,with no significant difference between the groups（P0.05）.The incidences of cardiotoxicity,alopecia and vomiting were higher in the CHOP group than in CTOP group（P0.05））.Conclusion CTOP（with THP） regimen may be more effective in treating PTCL with lower toxicity and better long-term survival.Further clinical trial is warranted to explore the efficacy in the elderly.

关 键 词：外周T细胞淋巴瘤 吡喃阿霉素 阿霉素 

分 类 号：R733.1[医药卫生—肿瘤]